SORRENTO THERAPEUTICS WKN: A1W8DY ISIN: US83587F2020 Kürzel: SRNE Forum: Aktien Thema: Hauptdiskussion

Steigen wäre mir mal lieber, aber würden jetzt News kommen würde sie wieder fallen 🤣🤣

Oh sie hält sich 😳😇

Sie hält sich gut heute, das zählt

Das stimmt, Murderna und Co. sehen blass aus heute

Emotionen geil Caesar 😂😂😂

Freue mich jedenfalls über unser Grün, in diesem Vaccine-Blutbad 😂

Ja sah auch gut aus, war auch nicht gegen dich gerichtet

Das ist eher ein leises fürzien🙄

Ist ja gut 😁😁 Fand halt den Sprung von $6,38 auf $6,77 in 10 Min schon beeindruckend

6 Cent grün 🙈

Richtiges Feuerwerk 😜

Naja "explodiert"

Explodiert, aber noch weiß keiner warum 🚀🚀🚀🚀

Sehe kaum einen Unterschied

Die neue Präsentationsseite ist schon mal um Welten besser, als zuvor

Sorrento: Is an inflection point near? Sorrento has quickly ratcheted up its research and development apparatus this year to become a one stop shop for all things COVID-19. Specifically, the biotech has a vaccine under development, neutralizing antibodies in the clinic, multiple molecular diagnostics in the pipeline, and a rescue therapy -- abivertinib -- in phase 2 development. Despite this flurry of clinical development, however, Sorrento isn't widely considered a leader in any of these therapeutic areas for the pandemic. Eli Lilly and Regeneron Pharmaceuticals will likely have their COVID-19 antibodies on the market several months ahead of Sorrento's candidates. The biopharma also doesn't appear to be a real contender in the vaccine space based on the current state of play -- at least from a commercial standpoint. As things stand now, Sorrento's biggest opportunity in COVID-19 appears to be in the realm of detection, with its COVI-Track and COVI-Trace product candidates. However, it's not altogether clear how big of a value proposition these product candidates actually represent. Wall Street once thought they were worth several hundred million in sales, but the field has matured significantly over the last few months. What's the bottom line? Sorrento clearly needs a regulatory win in the COVID-19 arena soon. The space is quickly filling up with competitors across the board, and the company is in real danger of being left behind. This beaten-down biotech stock, in turn, arguably isn't an attractive comeback play until management achieves this all-important operational goal https://www.nasdaq.com/articles/novavax-and-sorrento-therapeutics%3A-are-these-beaten-down-coronavirus-stocks-a-bargain-2020